Impact of Intravascular Brachytherapy on Patient-Reported Outcomes in Patients with Coronary Artery Disease.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
12 2020
Historique:
received: 24 04 2020
revised: 21 05 2020
accepted: 21 05 2020
pubmed: 18 6 2020
medline: 13 8 2021
entrez: 18 6 2020
Statut: ppublish

Résumé

Intravascular brachytherapy (VBT) is an established treatment for the management of in-stent restenosis (ISR). However, whether VBT is associated with improved patient reported outcomes unknown. We evaluated 51 consecutive patients undergoing VBT in one or more coronary arteries from January 2018 to September 2019. Data on baseline characteristics, procedural outcomes and adverse events were obtained. All patients completed the Seattle Angina Questionnaire - 7 (SAQ-7) form before and after VBT at 1 month and 6 months. The mean age was 69 ± 9 years and 29 (57%) of patients were males. Procedural success was 94.1%. The mean summary SAQ-7 score improved significantly (53.2 ± 21 vs. 83 ± 19, p < .001) at 30-days. The median Quality of Life (QoL) component of SAQ-7 score was 31.3 (Interquartile Range [IQR]: 18.8, 62.5) and improved to 82.5 (IQR: 62.5, 100), p < .001 at 30 days and 87.5 [IQR: 75, 100), p < .001 at last follow up. Likewise, the median angina frequency component of the SQL-7 score pre-VBT was 55 (IQR: 45, 80) and improved significantly to 90 (IQR: 60, 100) at 30-days, p < .001 and 100 [IQR: 68.8, 100], p = .02 at last follow up. Lastly, the median activity component of the SAQ-7 score improved from 83.3 (IQR: 60-100) to 100 (IQR: 83, 100), p = .01 at 30-days. Thus, results were evident as early as 1 month and sustained at median follow up of 17 months. VBT is associated with improvement in patient reported outcome measures at short term and long term follow up.

Sections du résumé

BACKGROUND
Intravascular brachytherapy (VBT) is an established treatment for the management of in-stent restenosis (ISR). However, whether VBT is associated with improved patient reported outcomes unknown.
METHODS
We evaluated 51 consecutive patients undergoing VBT in one or more coronary arteries from January 2018 to September 2019. Data on baseline characteristics, procedural outcomes and adverse events were obtained. All patients completed the Seattle Angina Questionnaire - 7 (SAQ-7) form before and after VBT at 1 month and 6 months.
RESULTS
The mean age was 69 ± 9 years and 29 (57%) of patients were males. Procedural success was 94.1%. The mean summary SAQ-7 score improved significantly (53.2 ± 21 vs. 83 ± 19, p < .001) at 30-days. The median Quality of Life (QoL) component of SAQ-7 score was 31.3 (Interquartile Range [IQR]: 18.8, 62.5) and improved to 82.5 (IQR: 62.5, 100), p < .001 at 30 days and 87.5 [IQR: 75, 100), p < .001 at last follow up. Likewise, the median angina frequency component of the SQL-7 score pre-VBT was 55 (IQR: 45, 80) and improved significantly to 90 (IQR: 60, 100) at 30-days, p < .001 and 100 [IQR: 68.8, 100], p = .02 at last follow up. Lastly, the median activity component of the SAQ-7 score improved from 83.3 (IQR: 60-100) to 100 (IQR: 83, 100), p = .01 at 30-days. Thus, results were evident as early as 1 month and sustained at median follow up of 17 months.
CONCLUSION
VBT is associated with improvement in patient reported outcome measures at short term and long term follow up.

Identifiants

pubmed: 32546383
pii: S1553-8389(20)30315-8
doi: 10.1016/j.carrev.2020.05.032
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1550-1554

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors report no conflict of interest.

Auteurs

Sahil Rawal (S)

University Medical Center, Phoenix, AZ, USA.

Abhishek C Sawant (AC)

University Medical Center, Phoenix, AZ, USA.

Meenakshi Sridhar (M)

University Medical Center, Phoenix, AZ, USA.

Muhammad Chaudhry (M)

University Medical Center, Phoenix, AZ, USA.

Srilekha Sridhara (S)

University Medical Center, Phoenix, AZ, USA.

Edward Distler (E)

University Medical Center, Phoenix, AZ, USA.

Sridevi Challa (S)

University Medical Center, Phoenix, AZ, USA.

Linda Parone (L)

University Medical Center, Phoenix, AZ, USA.

Siamac Yazdchi (S)

University Medical Center, Phoenix, AZ, USA.

Janelle Rodriguez (J)

University Medical Center, Phoenix, AZ, USA.

Kelly Daus (K)

University Medical Center, Phoenix, AZ, USA.

Ashish Pershad (A)

University Medical Center, Phoenix, AZ, USA. Electronic address: ashish.pershad@bannerhealth.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH